PT - JOURNAL ARTICLE AU - Carl Marincowitz AU - Laura Sutton AU - Tony Stone AU - Richard Pilbery AU - Richard Campbell AU - Benjamin Thomas AU - Janette Turner AU - Peter A. Bath AU - Fiona Bell AU - Katie Biggs AU - Madina Hasan AU - Frank Hopfgartner AU - Suvodeep Mazumdar AU - Jennifer Petrie AU - Steve Goodacre TI - Prognostic accuracy of triage tools for adults with suspected COVID-19 in a pre-hospital setting: an observational cohort study AID - 10.1101/2021.07.27.21261031 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.27.21261031 4099 - http://medrxiv.org/content/early/2021/07/29/2021.07.27.21261031.short 4100 - http://medrxiv.org/content/early/2021/07/29/2021.07.27.21261031.full AB - Study Objective Tools proposed to triage patient acuity in COVID-19 infection have only been validated in hospital populations. We estimated the accuracy of five risk-stratification tools recommended to predict severe illness and compare accuracy to existing clinical decision-making in a pre-hospital setting.Methods An observational cohort study using linked ambulance service data for patients attended by EMS crews in the Yorkshire and Humber region of England between 18th March 2020 and 29th June 2020 was conducted to assess performance of the PRIEST tool, NEWS2, the WHO algorithm, CRB-65 and PMEWS in patients with suspected COVID-19 infection. The primary outcome was death or need for organ support.Results Of 7549 patients in our cohort, 17.6% (95% CI:16.8% to 18.5%) experienced the primary outcome. The NEWS2, PMEWS, PRIEST tool and WHO algorithm identified patients at risk of adverse outcomes with a high sensitivity (>0.95) and specificity ranging from 0.3 (NEWS2) to 0.41 (PRIEST tool). The high sensitivity of NEWS2 and PMEWS was achieved by using lower thresholds than previously recommended. On index assessment, 65% of patients were transported to hospital and EMS decision to transfer patients achieved a sensitivity of 0.84 (95% CI 0.83 to 0.85) and specificity of 0.39 (95% CI 0.39 to 0.40).Conclusion Use of NEWS2, PMEWS, PRIEST tool and WHO algorithm could improve sensitivity of EMS triage of patients with suspected COVID-19 infection. Use of the PRIEST tool would improve sensitivity of triage without increasing the number of patients conveyed to hospital.Competing Interest StatementThe authors have declared no competing interest.Clinical Trialhttp://www.isrctn.com/ISRCTN28342533Funding StatementCM is a National Institute for Health Research (NIHR) Clinical Lecturer in Emergency Medicine (Grant Number Not Applicable/NA). This publication presents independent research funded by the National Institute for Health Research and University of Sheffield. The views expressed are those of the author(s) and not necessarily those of the University of Sheffield, the NHS, the NIHR or the Department of Health and Social CareAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The North West Haydock Research Ethics Committee gave a favourable opinion on the PAINTED study on 25th June 2012 (reference 12/NW/0303) and on the updated PRIEST study on 23rd March 2020, including the analysis presented here. The Confidentiality Advisory Group of the NHS Health Research Authority granted approval to collect data without patient consent in line with Section 251 of the National Health Service Act 2006. Access to data collected by NHS Digital was recommended for approval by its Independent Group Advising on the Release of Data (IGARD) on 11th September 2021 having received additional recommendation for approval for access to GP records from the Profession Advisory Group (PAG) on 19th August 2021.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used for this study are subject to data sharing agreements with NHS Digital and Yorkshire Ambulance Service which prohibits further sharing of individual level data. The data sets used are obtainable from these organisations subject to necessary authorisations and approvals.